Bulk ingredients

(Image: BernardaSv)

AMRI awarded seven-year NIH contract

By Melissa Fassbender

AMRI will support the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies under a seven-year contract with the NIH.

(Image: WuXi AppTec Co., Ltd.)

WuXi AppTec IPO tops $353m

By Melissa Fassbender

The Chinese contract research and development company WuXi AppTec has raised more than $353m in its initial public offering of common stock on the Shanghai Stock Exchange.

(Image: iStock/daizuoxin)

News in brief

BioDuro teams up with API developer Porton

By Melissa Fassbender

The San Diego-CA-based contract research, development, and manufacturing organization (CDMO), BioDuro, has announced a cooperation agreement with Porton Pharma Solutions.

(Image: iStock/thomas-bethge)

Reports revisited: What we learned this year

By Melissa Fassbender

Outsourcing models examined, market shifts scrutinized, and trial tribulations analyzed – take a look back at some of the top reports published in 2017.

(Image: Getty/marchmeena29)

4 trends driving industry priorities in 2018

By Melissa Fassbender

Commercial transformation could reach new heights in 2018, says inVentiv – as new expectations (and possibilities) reshape traditional models.

(Image: Getty/RomoloTavani)

Guest article

3 global trends driving transformations in healthcare product development

By Sudip S. Parikh, PhD, senior vice president & managing director, DIA Americas

The healthcare product development ecosystem is undergoing massive changes. Significant transformations are underway in how drugs and medical devices are researched, developed, manufactured, and approved.

Outsourcing-Pharma's Hiring and Firing Roundup May '17

People on the move

Outsourcing-Pharma's Hiring and Firing Roundup May '17

By Melissa Fassbender

This month’s roundup includes new executive leadership teams, hires on both sides of the Atlantic for CRO Smithers Viscient, a new VP and medical director at Clinipace, among others.